U.S. patent application number 16/172411 was filed with the patent office on 2019-10-17 for crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate.
The applicant listed for this patent is Axovant Sciences GmbH. Invention is credited to Richard Chesworth, Takayuki Ishige, Muneki Kishida, Patricia Oliver-Shaffer, Gideon Shapiro.
Application Number | 20190315736 16/172411 |
Document ID | / |
Family ID | 44121296 |
Filed Date | 2019-10-17 |
United States Patent
Application |
20190315736 |
Kind Code |
A1 |
Oliver-Shaffer; Patricia ;
et al. |
October 17, 2019 |
Crystalline Form of
(R)-7-Chloro-N-(Quinuclidin-3-YL)benzo[B]thiophene-2-Carboxamide
Hydrochloride Monohydrate
Abstract
Crystalline Forms I and II of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate and compositions, methods of manufacture
and therapeutic uses thereof are described.
Inventors: |
Oliver-Shaffer; Patricia;
(Acton, MA) ; Shapiro; Gideon; (Gainesville,
FL) ; Chesworth; Richard; (Concord, MA) ;
Kishida; Muneki; (Osaka, JP) ; Ishige; Takayuki;
(Osaka, JP) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Axovant Sciences GmbH |
Basel |
|
CH |
|
|
Family ID: |
44121296 |
Appl. No.: |
16/172411 |
Filed: |
October 26, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15908254 |
Feb 28, 2018 |
|
|
|
16172411 |
|
|
|
|
15656829 |
Jul 21, 2017 |
|
|
|
15908254 |
|
|
|
|
15375925 |
Dec 12, 2016 |
|
|
|
15656829 |
|
|
|
|
15002163 |
Jan 20, 2016 |
9550767 |
|
|
15375925 |
|
|
|
|
14795595 |
Jul 9, 2015 |
9273044 |
|
|
15002163 |
|
|
|
|
14184453 |
Feb 19, 2014 |
9108961 |
|
|
14795595 |
|
|
|
|
13698759 |
Apr 3, 2013 |
8710227 |
|
|
PCT/US2011/036844 |
May 17, 2011 |
|
|
|
14184453 |
|
|
|
|
61345363 |
May 17, 2010 |
|
|
|
61352092 |
Jun 7, 2010 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 9/4841 20130101;
A61P 25/00 20180101; C07B 2200/13 20130101; C07D 453/02 20130101;
A61P 25/16 20180101; A61P 25/28 20180101; A61P 25/18 20180101; A61K
31/439 20130101; A61P 25/14 20180101; A61P 43/00 20180101; C30B
29/54 20130101; C30B 7/08 20130101; A61K 9/4833 20130101 |
International
Class: |
C07D 453/02 20060101
C07D453/02; A61K 31/439 20060101 A61K031/439; C30B 29/54 20060101
C30B029/54; A61K 9/48 20060101 A61K009/48 |
Claims
1. A crystalline Form II of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate, characterized by an x-ray powder
diffraction pattern having peaks expressed as 20 at: i) one or both
of 21.16 and 21.38.+-.0.20 degrees when measured against an
internal silicon standard; and ii) at least four peaks selected
from a group of peaks consisting of: 4.48, 9.00, 13.58, 15.62,
16.48, 19.02, 19.44, 22.46, and 25.00.+-.0.20 degrees when measured
against an internal silicon standard.
2. The crystalline Form II of claim 1, characterized by an x-ray
powder diffraction pattern, wherein at least six peaks are selected
from the group of peaks.
3. The crystalline Form II of claim 1, characterized by an x-ray
powder diffraction pattern, wherein at least eight peaks are
selected from the group of peaks.
4. The crystalline Form II of claim 1, characterized by an x-ray
powder diffraction pattern, wherein all of the peaks are selected
from the group of peaks.
5. A pharmaceutical composition comprising the crystalline Form II
of claim 1.
6. The pharmaceutical composition of claim 5, wherein the
pharmaceutical composition is for the treatment of cognitive loss
in a subject suffering from Alzheimer's disease.
7. The pharmaceutical composition of claim 5, wherein the
pharmaceutical composition is for the treatment of cognitive loss
in a subject suffering from Schizophrenia.
8. The pharmaceutical composition of claim 5, wherein the
pharmaceutical composition is for the improvement of cognition in a
subject suffering from Alzheimer's disease.
9. The pharmaceutical composition of claim 5, wherein the
pharmaceutical composition is for the improvement of cognition in a
subject suffering from Schizophrenia.
10. A pharmaceutical composition comprising the crystalline Form II
of claim 2.
11. The pharmaceutical composition of claim 10, wherein the
pharmaceutical composition is for the treatment of cognitive loss
in a subject suffering from Alzheimer's disease.
12. The pharmaceutical composition of claim 10, wherein the
pharmaceutical composition is for the treatment of cognitive loss
in a subject suffering from Schizophrenia.
13. The pharmaceutical composition of claim 10, wherein the
pharmaceutical composition is for the improvement of cognition in a
subject suffering from Alzheimer's disease.
14. The pharmaceutical composition of claim 10, wherein the
pharmaceutical composition is for the improvement of cognition in a
subject suffering from Schizophrenia.
15. A pharmaceutical composition comprising the crystalline Form II
of claim 3.
16. The pharmaceutical composition of claim 15, wherein the
pharmaceutical composition is for the treatment of cognitive loss
in a subject suffering from Alzheimer's disease.
17. The pharmaceutical composition of claim 15, wherein the
pharmaceutical composition is for the treatment of cognitive loss
in a subject suffering from Schizophrenia.
18. The pharmaceutical composition of claim 15, wherein the
pharmaceutical composition is for the improvement of cognition in a
subject suffering from Alzheimer's disease.
19. The pharmaceutical composition of claim 15, wherein the
pharmaceutical composition is for the improvement of cognition in a
subject suffering from Schizophrenia.
20. A pharmaceutical composition comprising the crystalline Form II
of claim 4.
21-44. (canceled)
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 15/908,254, filed Feb. 28, 2018, which is further a
continuation of U.S. application Ser. No. 15/656,829, filed Jul.
21, 2017, which is further a continuation of U.S. application Ser.
No. 15/375,925, filed Dec. 12, 2016, which is further a
continuation of U.S. application Ser. No. 15/002,163, filed Jan.
20, 2016, now U.S. Pat. No. 9,550,767, which is further a
continuation of U.S. application Ser. No. 14/795,595, filed Jul. 9,
2015, now U.S. Pat. No. 9,273,044, which is further a continuation
of U.S. application Ser. No. 14/184,453, filed Feb. 19, 2014, now
U.S. Pat. No. 9,108,961, which is further a continuation of U.S.
application Ser. No. 13/698,759, filed Apr. 3, 2013, now U.S. Pat.
No. 8,710,227, which is the National Phase of International
Application No. PCT/US2011/036844, filed May 17, 2011, which
designated the United States and published in English, and further
claims the benefit of both U.S. Provisional Application No.
61/352,092, filed Jun. 7, 2010, and U.S. Provisional Application
No. 61/345,363, filed May 17, 2010. The foregoing related
applications, in their entirety, are incorporated herein by
reference.
FIELD OF THE INVENTION
[0002] The present disclosure relates to crystalline forms of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate and compositions, methods of manufacture
and therapeutic uses thereof.
BACKGROUND OF THE INVENTION
[0003] The endogenous neurotransmitter acetylcholine (Ach) mediates
diverse physiological functions in the peripheral and central
nervous systems (CNS) via muscarinic and nicotinic subclasses of
acetylcholine receptors (AChRs). The nicotinic acetylcholine
receptors (nAChRs) are ligand-gated cell surface ion channels that
are selectively activated by the natural product nicotine. The
diverse molecular subtypes or variants of nicotinic acetylcholine
receptor are based on the pentameric structure of the receptor. The
nAChR subtypes are formed from diverse pentameric combinations of
nine molecularly distinct alpha subunits and four molecularly
distinct beta subunits. A particularly interesting molecular target
for therapeutic intervention is the alpha-7 nicotinic receptor
subtype, which is comprised of five alpha-7 monomeric subunits.
Thus, agonists which are selective for the alpha-7 receptor have
potential to treat a range of diseases. Alpha-7 agonists are
expected to be especially useful for the treatment of CNS disorders
associated with cognitive deficits. This expectation is based on
beneficial effects of alpha-7 receptor activation on cognition,
learning and memory. At the same time, selective alpha-7 agonists
are expected to cause fewer or less severe undesirable side
effects, e.g. nausea, vomiting, tachycardia, which are mediated by
the activation of certain other nicotinic receptor subtypes as for
example by the non-selective agonist nicotine.
[0004] As such, there is a need for additional selective alpha-7
agonists for the treatment of CNS disorders associated with
cognitive deficits.
SUMMARY OF THE INVENTION
[0005] Accordingly, the present invention is directed to novel
crystalline compounds for use in the treatment of CNS disorders
associated with cognitive deficits. In particular, the invention
provides crystalline forms, i.e., Form I and Form II, of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate having the following formula.
##STR00001##
[0006] The invention further provides (a) pharmaceutical
compositions comprising one of the crystalline forms, (b) methods
for the treatment and/or prophylaxis of a condition in which
administration of an .alpha.7 nicotinic receptor agonist may be
expected to be therapeutic using one of the crystalline forms, and
(c) methods of manufacturing one of the crystalline forms.
BRIEF DESCRIPTION OF THE DRAWINGS
[0007] FIG. 1 is a phase diagram for Form I and Form II.
[0008] FIG. 2 depicts an X-ray powder diffraction (XRPD) spectrum
for Form X.
[0009] FIG. 3 is a graph depicting the relationship between water
activity and volume fraction of water in acetonitrile/water systems
at various temperatures.
[0010] FIG. 4 depicts a diagram of Form I and Form II using plots
of temperature against the value of water activity.
[0011] FIGS. 5A and 5B depict an X-ray powder diffraction (XRPD)
spectrum for Form I.
[0012] FIGS. 6A and 6B depict an X-ray powder diffraction (XRPD)
spectrum for Form II.
DETAILED DESCRIPTION OF THE INVENTION
[0013] The present invention, including crystalline forms, methods,
and pharmaceutical compositions will be described with reference to
the following definitions that, for convenience, are set forth
below. Unless otherwise specified, the below terms used herein are
defined as follows.
I. Definitions
[0014] As used herein and unless otherwise specified, the term
"crystal forms," "crystalline forms" and related terms herein refer
to solid forms that are crystalline. Crystal forms include
single-component crystal forms and multiple-component crystal
forms, and include, but are not limited to, polymorphs, solvates,
hydrates, and/or other molecular complexes. In one embodiment, the
crystalline forms of the invention are monohydrates. In certain
embodiments, a crystalline form is substantially pure, isolated or
enriched in one crystalline form, and/or is substantially free of
amorphous forms and/or other crystal forms.
[0015] As used herein and unless otherwise specified, the term
"crystalline" and related terms used herein, when used to describe
a compound, substance, modification, material, component or
product, unless otherwise specified, mean that the compound,
substance, modification, material, component or product is
substantially crystalline as determined by X-ray diffraction. See,
e.g., Remington: The Science and Practice of Pharmacy, 21.sup.st
edition, Lippincott, Williams and Wilkins, Baltimore, Md. (2005);
The United States Pharmacopeia, 23.sup.rd ed., 1843-1844
(1995).
[0016] Moreover, more detailed characterizations techniques for
characterizing crystal forms and amorphous forms may include, but
are not limited to, thermal gravimetric analysis (TGA),
differential scanning calorimetry (DSC), X-ray powder
diffractometry (XRPD), single-crystal X-ray diffractometry,
vibrational spectroscopy, e.g., infrared (IR) and Raman
spectroscopy, solid-state and solution nuclear magnetic resonance
(NMR) spectroscopy, optical microscopy, hot stage optical
microscopy, scanning electron microscopy (SEM), electron
crystallography and quantitative analysis, particle size analysis
(PSA), surface area analysis, solubility measurements, dissolution
measurements, elemental analysis and Karl Fischer analysis.
Characteristic unit cell parameters may be determined using one or
more techniques such as, but not limited to, X-ray diffraction and
neutron diffraction, including single-crystal diffraction and
powder diffraction. Techniques useful for analyzing powder
diffraction data include profile refinement, such as Rietveld
refinement, which may be used, e.g., to analyze diffraction peaks
associated with a single phase in a sample comprising more than one
solid phase. Other methods useful for analyzing powder diffraction
data include unit cell indexing, which allows one of skill in the
art to determine unit cell parameters from a sample comprising
crystalline powder. Furthermore, it would be understood by the
ordinarily skilled artisan that identification of a crystal may be
made using one of these techniques, e.g., X-ray powder
diffractometry, and may be confirmed using additional noted
characterization techniques.
[0017] As used herein and unless otherwise specified, a sample
comprising a particular crystal form or amorphous form that is
"substantially pure," contains the particular crystal form or
amorphous form in a chemical and/or physical purity greater than
about 75%, e.g., 80%, e.g., 85%, e.g., 90%, e.g., 91%, e.g., 92%,
e.g., 93%, e.g., 94%, e.g., 95%, e.g., 96%, e.g., 97%, e.g., 98%,
e.g., 99%, e.g., 99.25%, e.g., 99.50%, e.g., 99.75%, e.g., 99.9%,
e.g., 100% physically and/or chemically pure. In certain
embodiments, the particular crystal form or amorphous form is
greater than about 90%, e.g., 91%, e.g., 92%, e.g., 93%, e.g., 94%,
e.g., 95%, e.g., 96%, e.g., 97%, e.g., 98%, e.g., 99%, e.g.,
99.25%, e.g., 99.50%, e.g., 99.75%, e.g., 99.9%, e.g., 100%
physically and/or chemically pure. In particular embodiments, the
particular crystal form or amorphous form is greater than about
95%, e.g., 96%, e.g., 97%, e.g., 98%, e.g., 99%, e.g., 99.25%,
e.g., 99.50%, e.g., 99.75%, e.g., 99.9%, e.g., 100% physically
and/or chemically pure. In specific embodiments, the particular
crystal form or amorphous form is greater than about 99%, e.g.,
99.25%, e.g., 99.50%, e.g., 99.75%, e.g., 99.9%, e.g., 100%
physically and/or chemically pure.
[0018] As used herein and unless otherwise specified, a sample or
composition that is "substantially free" of one or more other solid
forms and/or other chemical compounds means that the composition
contains, in particular embodiments, less than about 25%, e.g.,
20%, e.g., 15%, e.g., 10%, e.g., 9%, e.g., 8%, e.g., 7%, e.g., 6%,
e.g., 5%, e.g., 4%, e.g., 3%, e.g., 2%, e.g., 1%, e.g., 0.75%,
e.g., 0.5%, e.g., 0.25%, e.g., or 0.1% percent by weight of one or
more amorphous forms and/or other crystal forms. In certain
embodiments, the composition contains less than 10%, e.g., 9%,
e.g., 8%, e.g., 7%, e.g., 6%, e.g., 5%, e.g., 4%, e.g., 3%, e.g.,
2%, e.g., 1%, e.g., 0.75%, e.g., 0.5%, e.g., 0.25%, e.g., or 0.1%
percent by weight of one or more amorphous forms and/or other
crystal forms. In particular embodiments, the composition contains
less than 5%, e.g., 4%, e.g., 3%, e.g., 2%, e.g., 1%, e.g., 0.75%,
e.g., 0.5%, e.g., 0.25%, e.g., or 0.1% percent by weight of one or
more amorphous forms and/or other crystal forms. In specific
embodiments, the composition contains less than 1%, e.g., 0.75%,
e.g., 0.5%, e.g., 0.25%, e.g., or 0.1% percent by weight of one or
more amorphous forms and/or other crystal forms. In certain
embodiments, a crystal form of a substance may be physically and/or
chemically pure.
[0019] As used herein and unless otherwise specified, the terms
"polymorphs," "polymorphic forms" and related terms herein, refer
to two or more crystal forms that consist essentially of the same
molecule, molecules, and/or ions. Different polymorphs may have
different physical properties such as, e.g., melting temperature,
heat of fusion, solubility, dissolution properties and/or
vibrational spectra, as a result of the arrangement or conformation
of the molecules and/or ions in the crystal lattice. The
differences in physical properties may affect pharmaceutical
parameters such as storage stability, compressibility and density
(important in formulation and product manufacturing), and
dissolution rate (an important factor in bioavailability).
Differences in stability can result from changes in chemical
reactivity (e.g., differential oxidation, such that a dosage form
discolors more rapidly when comprised of one polymorph than when
comprised of another polymorph) or mechanical changes (e.g.,
tablets crumble on storage as a kinetically favored polymorph
converts to thermodynamically more stable polymorph) or both (e.g.,
tablets of one polymorph are more susceptible to breakdown at high
humidity). As a result of solubility/dissolution differences, in
the extreme case, some solid-state transitions may result in lack
of potency or, at the other extreme, toxicity. In addition, the
physical properties may be important in processing (e.g., one
polymorph might be more likely to form solvates or might be
difficult to filter and wash free of impurities, and particle shape
and size distribution might be different between polymorphs).
[0020] The terms "hydrate" and "hydrated" refer to a solvate
wherein the solvent comprises water. "Polymorphs of solvates"
refers to the existence of more than one crystal form for a
particular solvate composition. Similarly, "polymorphs of hydrates"
refers to the existence of more than one crystal form for a
particular hydrate composition.
[0021] As used herein and unless otherwise specified, the term
"amorphous," "amorphous form," and related terms used herein,
describe that the substance, component or product in question is
not substantially crystalline as determined by X-ray diffraction.
In particular, the term "amorphous form" describes a disordered
solid form, i.e., a solid form lacking long range crystalline
order. In certain embodiments, an amorphous form of a substance may
be substantially free of other amorphous forms and/or crystal
forms. In other embodiments, an amorphous form of a substance may
contain less than about 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%,
30%, 35%, 40%, 45% or 50% of one or more other amorphous forms
and/or crystal forms on a weight basis. In certain embodiments, an
amorphous form of a substance may be physically and/or chemically
pure. In certain embodiments, an amorphous form of a substance be
about 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91% or 90% physically
and/or chemically pure.
[0022] As used herein and unless otherwise specified, the terms
"about" and "approximately," when used in connection with a numeric
value or a range of values which is provided to characterize a
particular solid form, e.g., a specific temperature or temperature
range, such as, e.g., that describing a DSC or TGA thermal event,
including, e.g., melting, dehydration, desolvation or glass
transition events; a mass change, such as, e.g., a mass change as a
function of temperature or humidity; a solvent or water content, in
terms of, e.g., mass or a percentage; or a peak position, such as,
e.g., in analysis by IR or Raman spectroscopy or XRFD; indicate
that the value or range of values may deviate to an extent deemed
reasonable to one of ordinary skill in the art while still
describing the particular solid form. For example, in particular
embodiments, the terms "about" and "approximately," when used in
this context and unless otherwise specified, indicate that the
numeric value or range of values may vary within 25%, 20%, 15%,
10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1.5%, 1%, 0.5%, or 0.25% of
the recited value or range of values.
[0023] As used herein, and unless otherwise specified, the terms
"treat," "treating" and "treatment" refer to the eradication or
amelioration of a disease or disorder, or of one or more symptoms
associated with the disease or disorder. In certain embodiments,
the terms refer to minimizing the advancement or worsening of the
disease or disorder resulting from the administration of a compound
of the invention to a patient with such a disease or disorder. In
some embodiments, the terms refer to the administration of a
compound provided herein, with or without other additional active
agents, after the onset of symptoms of the particular disease. The
terms "treating", "treatment", or the like, as used herein covers
the treatment of a disease-state in a subject, e.g., a mammal, and
includes at least one of: (i) inhibiting the disease-state, i.e.,
partially or completely arresting its development; (ii) relieving
the disease-state, i.e., causing regression of symptoms of the
disease-state, or ameliorating a symptom of the disease; and (iii)
reversal or regression of the disease-state, preferably eliminating
or curing of the disease. In a particular embodiment the terms
"treating", "treatment", or the like, covers the treatment of a
disease-state in a a mammal, e.g., a primate, e.g., a human, and
includes at least one of (i), (ii) and (iii) above. As is known in
the art, adjustments for systemic versus localized delivery, age,
body weight, general health, sex, diet, time of administration,
drug interaction and the severity of the condition may be
necessary, and will be ascertainable with routine experimentation
by one of ordinary skill in the art.
[0024] As used herein, and unless otherwise specified, the terms
"prevent," "preventing" and "prevention" refer to the prevention of
the onset, recurrence or spread of a disease or disorder, or of one
or more symptoms thereof. In certain embodiments, the terms refer
to the administration of a compound provided herein to a subject,
with or without other additional active compound, prior to the
onset of symptoms, particularly to patients at risk of diseases or
disorders provided herein. The terms encompass the inhibition or
reduction of a symptom of the particular disease. Subjects with
familial history of a disease in particular are candidates for
preventive regimens in certain embodiments. In addition, subjects
who have a history of recurring symptoms are also potential
candidates for the prevention. In this regard, the term
"prevention" may be interchangeably used with the term
"prophylactic treatment." In certain embodiments, the prevention is
achieved by administration of a prophylactically effective amount
of a compound of the invention.
[0025] As used herein, and unless otherwise specified, a
"therapeutically effective amount" of a compound is an amount
sufficient to provide a therapeutic benefit in the treatment or
management of a disease or disorder, or to delay or minimize one or
more symptoms associated with the disease or disorder. A
therapeutically effective amount of a compound means an amount of
therapeutic agent, alone or in combination with other therapies,
which provides a therapeutic benefit in the treatment or management
of the disease or disorder. The term "therapeutically effective
amount" can encompass an amount that improves overall therapy,
reduces or avoids symptoms or causes of disease or disorder, or
enhances the therapeutic efficacy of another therapeutic agent.
[0026] As used herein, and unless otherwise specified, the terms
"manage," "managing" and "management" refer to preventing or
slowing the progression, spread or worsening of a disease or
disorder, or of one or more symptoms thereof. Often, the beneficial
effects that a subject derives from a prophylactic and/or
therapeutic agent do not result in a cure of the disease or
disorder. In this regard, the term "managing" encompasses treating
a subject who had suffered from the particular disease in an
attempt to prevent or minimize the recurrence of the disease.
[0027] As used herein, and unless otherwise specified, a
"prophylactically effective amount" of a compound is an amount
sufficient to prevent a disease or disorder, or prevent its
recurrence. A prophylactically effective amount of a compound means
an amount of therapeutic agent, alone or in combination with other
agents, which provides a prophylactic benefit in the prevention of
the disease. The term "prophylactically effective amount" can
encompass an amount that improves overall prophylaxis or enhances
the prophylactic efficacy of another prophylactic agent.
[0028] The term "composition" as used herein is intended to
encompass a product comprising the specified ingredients (and in
the specified amounts, if indicated), as well as any product which
results, directly or indirectly, from combination of the specified
ingredients in the specified amounts. The term "pharmaceutical
composition" encompasses compositions containing a compound of the
invention, e.g., crystal Form I or II, and a pharmaceutically
acceptable carrier. A "pharmaceutically acceptable carrier" is a
diluent, excipient or carrier that is compatible with the other
ingredients of the formulation and not deleterious to the recipient
thereof.
II. Compounds of the Invention
[0029] In one embodiment, the invention provides crystalline Form I
and Form II of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate having the following formula.
##STR00002##
[0030] For clarity, the alpha-7 receptor agonist compound
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride was disclosed in United States Patent Application
Publication No. US 2005-0119325. However, in contrast to the
present invention, such disclosure did not disclose or suggest the
present invention,
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate, nor did it disclose any crystal forms of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate.
[0031] In one embodiment, the invention provides a crystalline Form
I of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate, characterized by an x-ray powder
diffraction pattern having peaks expressed as 20 at one or both of
17.48 and 20.58.+-.0.20 degrees when measured against an internal
silicon standard.
[0032] In another embodiment, the invention provides the
crystalline Form I as defined above, characterized by an x-ray
powder diffraction pattern further having at least one peak
expressed as 2.theta. at 4.50, 9.04, 14.60, 15.14, 15.80, 16.60,
18.16, 18.44, 19.48, 21.74, and 25.46.+-.0.20 degrees when measured
against an internal silicon standard.
[0033] In another embodiment, the invention includes the
crystalline Form I as defined above, characterized by an x-ray
powder diffraction pattern further having at least two peaks
expressed as 2.theta. at 4.50, 9.04, 14.60, 15.14, 15.80, 16.60,
18.16, 18.44, 19.48, 21.74 and 25.46.+-.0.20 degrees when measured
against an internal silicon standard.
[0034] In yet another embodiment, the invention provides the
crystalline Form I as defined above, characterized by an x-ray
powder diffraction pattern further having at least four peaks
expressed as 2.theta. at 4.50, 9.04, 14.60, 15.14, 15.80, 16.60,
18.16, 18.44, 19.48, 21.74 and 25.46.+-.0.20 degrees when measured
against an internal silicon standard.
[0035] The invention further includes the crystalline Form I as
defined above, characterized by an x-ray powder diffraction pattern
further having at least six peaks expressed as 2.theta. at 4.50,
9.04, 14.60, 15.14, 15.80, 16.60, 18.16, 18.44, 19.48, 21.74 and
25.46.+-.0.20 degrees when measured against an internal silicon
standard.
[0036] The invention further includes the crystalline Form I as
defined above, characterized by an x-ray powder diffraction pattern
further having at least eight peaks expressed as 2.theta. at 4.50,
9.04, 14.60, 15.14, 15.80, 16.60, 18.16, 18.44, 19.48, 21.74 and
25.46.+-.0.20 degrees when measured against an internal silicon
standard.
[0037] The invention further provides the crystalline Form I as
defined above, characterized by an x-ray powder diffraction pattern
further having peaks expressed as 20 at 4.50, 9.04, 14.60, 15.14,
15.80, 16.60, 18.16, 18.44, 19.48, 21.74 and 25.46.+-.0.20 degrees
when measured against an internal silicon standard.
[0038] In another embodiment, the present invention provides a
crystalline Form II of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate, characterized by an x-ray powder
diffraction pattern having peaks expressed as 2.theta. at one or
both of 21.16 and 21.38.+-.0.20 degrees when measured against an
internal silicon standard.
[0039] In another embodiment, the present invention provides the
crystalline Form II as defined above, characterized by an x-ray
powder diffraction pattern further having at least one peak
expressed as 2.theta. at 4.48, 9.00, 13.58, 15.62, 16.48, 19.02,
19.44, 22.46 and 25.00.+-.0.20 degrees when measured against an
internal silicon standard.
[0040] In yet another embodiment, provided herein is the
crystalline Form II as defined above, characterized by an x-ray
powder diffraction pattern further having at least two peaks
expressed as 2.theta. at 4.48, 9.00, 13.58, 15.62, 16.48, 19.02,
19.44, 22.46 and 25.00.+-.0.2 degrees when measured against an
internal silicon standard.
[0041] In another embodiment, the present invention includes the
crystalline Form II as defined above, characterized by an x-ray
powder diffraction pattern further having at least four peaks
expressed as 2.theta. at 4.48, 9.00, 13.58, 15.62, 16.48, 19.02,
19.44, 22.46 and 25.00.+-.0.2 degrees when measured against an
internal silicon standard.
[0042] Further provided herein is the crystalline Form II as
defined above, characterized by an x-ray powder diffraction pattern
further having at least six peaks expressed as 2.theta. at 4.48,
9.00, 13.58, 15.62, 16.48, 19.02, 19.44, 22.46 and 25.00.+-.0.2
degrees when measured against an internal silicon standard.
[0043] Also provided here is the crystalline Form II as defined
above, characterized by an x-ray powder diffraction pattern further
having at least eight peaks expressed as 2.theta. at 4.48, 9.00,
13.58, 15.62, 16.48, 19.02, 19.44, 22.46 and 25.00.+-.0.2 degrees
when measured against an internal silicon standard.
[0044] In another embodiment, provided herein is the crystalline
Form II as defined above, characterized by an x-ray powder
diffraction pattern further having peaks expressed as 2.theta. at
4.48, 9.00, 13.58, 15.62, 16.48, 19.02, 19.44, 22.46 and
25.00.+-.0.2 degrees when measured against an internal silicon
standard.
III. Methods of the Invention
[0045] A. Methods of Use
[0046] In an embodiment, the present invention provides the
crystalline Form I for the treatment and/or prophylaxis of a
disease which can be treated or prevented by alpha-7 receptor
activation. In another embodiment, the present invention provides
crystalline Form II for the treatment and/or prophylaxis of a
disease which can be treated or prevented by alpha-7 receptor
activation.
[0047] In another embodiment, the present invention provides a
method of treating or preventing a disease which can be treated or
prevented by alpha-7 receptor activation comprising administering
to a subject crystalline Form I. In another embodiment, a method of
treating or preventing a disease which can be treated or prevented
by alpha-7 receptor activation comprising administering to a
subject crystalline Form II is provided.
[0048] In another embodiment, the present invention provides a
method for improving cognition or treating cognitive loss in a
subject comprising administering to a subject the crystalline Form
I. In another embodiment, the present invention provides the method
for improving cognition or treating cognitive loss by administering
to a subject the crystalline Form I wherein the subject is
suffering from a disorder selected from: attention deficit
disorder, attention deficit hyperactivity disorder, and Parkinson's
Disease. In another embodiment, the present invention provides the
method for improving cognition or treating cognitive loss by
administering crystalline Form I wherein the subject is suffering
from a disorder selected from Alzheimer's Disease and
schizophrenia.
[0049] In another embodiment, the present invention provides a
method of treating a disorder selected from attention deficit
disorder, attention deficit hyperactivity disorder, Parkinson's
Disease, Alzheimer's Disease and schizophrenia, the method
comprising administering to a subject the crystalline Form I. In
another embodiment, the present invention includes a method of
treating a subject that is at risk for developing a disorder
selected from: Alzheimer's disease, Parkinson's Disease and
schizophrenia, the method comprising administering to the subject
the crystalline Form I. In yet another embodiment, the present
invention includes a method of treating a subject over age 60,
comprising administering to the subject the crystalline Form I. In
a further embodiment, the present invention includes a method of
treating a subject for age-related memory loss, comprising
administering to the subject the crystalline Form I. In another
embodiment the present invention includes a method of treating a
subject for age-related memory loss, comprising administering to
the subject the crystalline Form I wherein the subject is over age
60.
[0050] In another embodiment, the present invention provides a
method for improving cognition or treating cognitive loss in a
subject comprising administering to a subject the crystalline Form
II. In another embodiment, the present invention provides the
method for improving cognition or treating cognitive loss by
administering crystalline Form II to a subject, wherein the subject
is suffering from a disorder selected from: attention deficit
disorder, attention deficit hyperactivity disorder, and Parkinson's
Disease. In another embodiment, the present invention provides the
method for improving cognition or treating cognitive loss by
administering crystalline Form II to a subject, wherein the subject
is suffering from a disorder selected from Alzheimer's Disease and
schizophrenia.
[0051] In another embodiment, the present invention provides a
method of treating a disorder selected from attention deficit
disorder, attention deficit hyperactivity disorder, Parkinson's
Disease, Alzheimer's Disease and schizophrenia, the method
comprising administering to a subject the crystalline Form II. In
another embodiment, the present invention includes a method of
treating a subject that is at risk for developing a disorder
selected from: Alzheimer's disease, Parkinson's Disease and
schizophrenia, the method comprising administering to the subject
the crystalline Form II. In yet another embodiment, the present
invention includes a method of treating a subject over age 60,
comprising administering to the subject the crystalline Form II. In
a further embodiment, the present invention includes a method of
treating a subject for age-related memory loss, comprising
administering to the subject the crystalline Form II. In another
embodiment the present invention includes a method of treating a
subject for age-related memory loss, comprising administering to
the subject the crystalline Form II wherein the subject is over age
60.
[0052] B. Methods of Preparation
[0053] It would be beneficial to provide
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate in a stable crystalline form. After
extensive studies, two types of stable crystalline forms were
identified: Form I and Form II. One crystalline form does not
convert to the other readily in solid condition because each of two
crystalline forms is stable. On the other hand, it was found that
when one crystalline form was dissolved in an aqueous solvent and
the crystallization was carried out from the solution, it was
difficult to predict which crystalline form was preferentially
produced. In addition, one form might be converted to the other or
a mixture of two forms quite easily in the solution under certain
conditions. Therefore the mechanism of crystallization was unclear,
and it was difficult to design methods for producing each form at
high purity. After extensive investigation, the inventors arrived
at the methods for selectively manufacturing each pure crystalline
form. The methods can be carried out using a variety of different
solvents.
[0054] A crystal form of a compound is usually obtained by: 1)
dissolving the compound in a solvent at a high temperature, where
the solubility of the product is high, 2) lowering the temperature
of the solution to cause crystallization of the compound, and 3)
isolating the resulting crystals.
[0055] However, solid state investigations revealed that there are
two enantiotropic crystalline forms of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate, and the present inventors discovered
that the usual crystallization procedure is apt to produce a
mixture of the two crystal forms of the compound. This is because
at higher temperatures, one crystal form of the compound is a
little more stable in a solvent system, whereas in at lower
temperatures, the other crystal form of the compound is a little
more stable in the same solvent system. This effect can be seen in
Examples 5, 6, 7 and 8. Furthermore, the boundary temperature for
converting from one form to the other was found to vary depending
on the solvent system in which the compound is dissolved.
[0056] The inventors extensively investigated the stable crystal
forms at various temperatures and in various solvent systems and
recognized that Form I and Form II of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate can be separately prepared based on the
relationship of temperature and water activity of the solvent
independently of the particular organic solvent. This recognition
led to the creation of novel methods for separately manufacturing
pure Form I and pure Form II.
[0057] In an embodiment, the present invention provides a method
for preparing a pharmaceutical composition, the method comprising
combining the crystalline form I with an excipient or
pharmaceutically acceptable carrier. In an embodiment, the method
further includes combining the crystalline form I with a liquid. In
a further embodiment, the method includes filling a capsule with a
composition comprising the crystalline form I.
[0058] In another embodiment, the present invention includes a
method for preparing a pharmaceutical composition comprising
combining the crystalline form II with an excipient or
pharmaceutically acceptable carrier. In an embodiment, the method
further includes combining the crystalline form II with a liquid.
In a further embodiment, the method includes filling a capsule with
a composition comprising the crystalline form II.
[0059] A method of manufacturing a crystalline Form I comprises:
(1) stirring
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride (hereinafter,
"(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride" includes any form of anhydrate, hydrate and solvate,
preferably anhydrate and hydrate) in an aqueous organic solvent
within the temperature-water activity range I, if required with
decreasing the temperature and/or water activity thereof, to form a
substantially pure crystalline Form I; and (2) isolating the
resulting crystalline Form I, wherein the temperature-water
activity range I is defined by the following relationship of the
temperature and the water activity of the aqueous organic solvent,
the water activity (x) of the aqueous organic solvent is from 0.16
to 0.73; and the temperature (T) of the aqueous organic solvent is
higher than (183x-64.2) and lower than the boiling temperature of
the aqueous organic solvent.
[0060] In an embodiment, the method of manufacturing crystalline
Form I includes a method where, in step (1) the initial state of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride in an aqueous organic solvent is a solution, and the
solution is stirred within the temperature-water activity range I
with decreasing the temperature and/or water activity thereof. In
another embodiment, the method of manufacturing crystalline Form I
includes a method where in step (1) the initial state of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride in an aqueous organic solvent is a suspension, and
the suspension is stirred within the temperature-water activity
range I, if required with decreasing the temperature and/or water
activity thereof. In a further embodiment, the method of
manufacturing crystalline Form I includes a method where in step
(1) the seed crystals of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride is added to the solution. In a still further
embodiment, the method of manufacturing crystalline Form I includes
a method where the seed crystals are Form I of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate.
[0061] In an embodiment the method of manufacturing crystalline
Form I includes a method where the water activity is from 0.29 to
0.59. In another embodiment, the method of manufacturing
crystalline Form I includes a method where the temperature is
between -10.degree. C. and 60.degree. C. and higher than the
following T: T=183x-57.6; wherein x is water activity of the
aqueous organic solvent and T is a temperature (.degree. C.). In
yet another embodiment the method of manufacturing crystalline Form
I includes a method where the end point temperature in step (1) is
between 0.degree. C. and 35.degree. C.
[0062] In an embodiment, the method of manufacturing crystalline
Form I includes a method where the aqueous organic solvent is
mixture of water and one or more of organic solvents which are
miscible with water and are selected from alcohols, ketones,
nitriles and ethers. In another embodiment, the method of
manufacturing crystalline Form I includes a method where the
aqueous organic solvent is mixture of water and one or more of
organic solvents which are miscible with water and are selected
from propanol, butanol, butanone and acetonitrile.
[0063] The present invention also includes a method of
manufacturing a crystalline Form II; comprising: (1) stirring
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride in an aqueous organic solvent within the
temperature-water activity range II, if required with decreasing
the temperature and/or water activity thereof, to form a
crystalline Form II, and (2) isolating the resulting crystalline
Form II, wherein the temperature-water activity range II is defined
by the following relationship of the temperature and the water
activity of the aqueous organic solvent, the water activity (x) of
the aqueous organic solvent is from 0.16 to 0.73; and the
temperature (T) of the aqueous organic solvent is lower than
(183x-64.2) and higher than the freezing-point temperature of the
aqueous organic solvent.
[0064] In an embodiment, the method of manufacturing crystalline
Form II includes the method where in step (1) the initial state of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride in an aqueous organic solvent is a solution, and the
solution is stirred within the temperature-water activity range II
with decreasing the temperature and/or water activity thereof. In
an embodiment, the method of manufacturing crystalline Form II
includes a method wherein in step (1) the initial state of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride in an aqueous organic solvent is a suspension, and
the suspension is stirred within the temperature-water activity
range II, optionally decreasing the temperature and/or water
activity thereof.
[0065] In another embodiment, the method of manufacturing
crystalline Form II includes a method wherein in step (1) the seed
crystals of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride is added to the solution. In yet another embodiment,
the method of manufacturing crystalline Form II includes a method
wherein the seed crystals are Form II of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate. In yet another embodiment, the method of
manufacturing crystalline Form II includes a method wherein the
water activity is from 0.29 to 0.59. In a further embodiment, the
method of manufacturing crystalline Form II includes a method
wherein the temperature is between -10.degree. C. and 60.degree. C.
and lower than the following T: T=183x-70.8; wherein x is water
activity of the aqueous organic solvent and T is a temperature
(.degree. C.). In an embodiment, the method of manufacturing
crystalline Form II includes a method wherein the end point
temperature in step (1) is between 0.degree. C. and 35.degree. C.
In an embodiment, the method of manufacturing crystalline Form II
includes a method wherein the aqueous organic solvent is mixture of
water and one or more of organic solvents which are miscible with
water and are selected from alcohols, ketones, nitriles and
ethers.
[0066] In another embodiment, the method of manufacturing
crystalline Form II includes a method wherein the aqueous organic
solvent is mixture of water and one or more of organic solvents
which are miscible with water and are selected from propanol,
butanol, butanone and acetonitrile.
[0067] The present invention also provides another method for
preparing the crystalline Form I, comprising: (a) heating 10-30% by
weight of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride in acetonitrile or an aqueous acetonitrile to between
60.degree. C. and the boiling point of the solution, (b) optionally
adding water to the mixture to fully dissolve the
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride; (c) cooling the solution until crystals are just
visible; (d) if the water content is greater than 3% volume/volume
when crystals are just visible, adding acetonitrile to the mixture
so that the water content is less than 3% volume/volume; (e)
cooling the resulting mixture to below 15.degree. C.; and (f)
isolating crystalline
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate.
[0068] In an embodiment, the method of preparing the crystalline
Form I includes the method as defined in steps (a) through (f)
above, wherein the water added in step (a) does not bring the water
content of the mixture above 30% volume/volume. In another
embodiment, the method of preparing the crystalline Form I includes
the method as defined in steps (a) through (f) above, wherein
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride is present at 15-25% by weight in step (a). In
another embodiment, the method of preparing the crystalline Form I
includes the method as defined in steps (a) through (f) above,
wherein
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride is present at 16-20% by weight in step (a). In
another embodiment, the method of preparing the crystalline Form I
includes the method as defined in steps (a) through (f) above,
wherein
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride is present at 17-19% by weight in step (a). In yet
another embodiment, the method of preparing the crystalline Form I
includes the method as defined in steps (a) through (f) above,
further comprising adding Form I
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate to the mixture after crystals are just
visible.
[0069] In yet another embodiment, the method of preparing the
crystalline Form I includes the method as defined in steps (a)
through (1) above, wherein step (c) comprises cooling the solution
to below 55.degree. C. In yet another embodiment, the method of
preparing the crystalline Form I includes the method as defined in
steps (a) through (f) above, wherein step (c) comprises cooling the
solution to below 50.degree. C.
[0070] Also included in the present invention is a method for
preparing the crystalline Form II, the method comprising: (a)
heating 5-15% by weight of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamid- e
hydrochloride in 2-butanol or an aqueous 2-butanol to between
60.degree. C. and the boiling point of the solution; (b) if the
water content is smaller than 5% volume/volume, adding water to the
mixture so that the water content is not less than 5%
volume/volume; (c) cooling the solution to below 10.degree. C.; (d)
keeping the resulting mixture to below 10.degree. C.; and (e)
isolating crystalline
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate.
[0071] The present invention further includes a method for
preparing the crystalline Form II, the method comprising: (a)
adding
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride to (i) acetonitrile or (ii) aqueous acetonitrile to
create a composition that is 10-20% by weight of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride; (b) optionally adding water to the composition to
make the water content 6-10%; (c) optionally cooling the solution
at below 10.degree. C.; (d) allowing crystals to form; and (e)
isolating crystalline
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate.
[0072] The crystalline Forms I and II are very stable in many
aspects. Both forms are stable under storage conditions. No
degradation products from either form were detected under the
storage conditions: 11% RH at 40.degree. C., 75% RH at 40.degree.
C., 11% RH at 60.degree. C. and 75% RH at 60.degree. C. after 2
weeks, and no degradation products from either form were detected
under the photo storage conditions: exposure to light (D65 lamp) of
1.2 million Lux hours at 25.degree. C. Both forms are also stable
under physical stress. The XRD charts of both forms were not
changed after compression experiments with a planar pestle (1000
kgf/cm.sup.2).
[0073] The pure crystalline Forms I and II can be manufactured by
the special methods, which are described herein.
[0074] Pure crystalline Form I can be manufactured by a method
which comprises: (1) stirring
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride in an aqueous organic solvent within the
temperature-water activity range I (as depicted in FIG. 4), if
required with decreasing the temperature and/or water activity
thereof, to form a substantially pure crystalline Form I, and (2)
isolating the resulting crystalline Form I.
[0075] Pure crystalline Form II can be manufactured by the method
which comprises: (1) stirring
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride in an aqueous organic solvent within the
temperature-water activity range II (as depicted in FIG. 4), if
required with decreasing the temperature and/or water activity
thereof, to form a crystalline Form II, and (2) isolating the
resulting crystalline Form II.
[0076] Water activity is a thermophysical coefficient used to
represent the energy status of the water in a system and is defined
as the vapor pressure of water above a sample divided by that of
pure water at the same temperature. It can be measured with a
capacitance hygrometer or a dew point hygrometer. It can be also
predicted by COSMO-RS method (Fluid Phase Equililbria, 172 (2000)
43-72).
[0077]
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride was prepared, for example, by the method described in
WO03/55878. 7-Chloro-benzo[b]thiophene-2-carboxylic acid was
reacted with carbonyldiimidazole to give
7-chloro-2-imidazolyl-carbonylbenzo[b]thiophene, followed by
reacting with (R)-3-aminoquinuclidine dihydrochloride to give
(R)-7-chloro-N-(quinuclidin-3 yl)benzo[b]thiophene-2-carboxamide
hydrochloride.
[0078]
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride used for the above manufacturing methods can be for
example crystals (e.g., Forms I, II, and mixtures thereof),
amorphous products, an oil or a solution, and preferably a
solution. The crystallization can be performed in the same vessel
after hydrochlorination. An aqueous organic solvent is a mixture of
water and one or more organic solvents. The preferable organic
solvents are water-miscible organic solvents, and more preferable
are for example alcohols (e.g., C.sub.1-6 alkanol such as methanol,
ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, and
C.sub.2-6 alkanediol such as ethylene glycol, propylene glycol),
ketones (e.g., C.sub.3-6 alkanone such as acetone, butanone),
nitriles (e.g., acetonitrile, propanonitrile) and ethers (e.g.
dimethoxyethane, tetrahydrofuran). Preferable solvents are
alcohols, nitriles and ketones, and more preferable are propanols,
butanols, butanone and acetonitrile.
[0079] In the present invention the solution is supersatured prior
to the formation of crystals. The boundary between the
temperature-water activity ranges for Forms I and II is shown in
FIG. 4 as a line which divides the domains of Forms I and II.
[0080] Crystal forms may be monitored during the production method.
Any analytical methods can be used for monitoring as long as it can
distinguish crystal forms, and XRD is one of most preferable
methods. In order to manufacture a pure form, stirring of the
mixture is continued until undesired form completely converts to
the desired form.
[0081] In the method for manufacturing Form I, Form X which is
different from both Forms I and II may appear temporally, but Form
X can be converted to Form I and disappears if stirring of the
mixture is continued.
IV. Pharmaceutical Compositions of the Invention
[0082] Provided also herein the present invention is a
pharmaceutical composition comprising the crystalline Form I. Also
provided herein is a pharmaceutical composition comprising the
crystalline Form II.
[0083] The crystalline Forms I and II may be used to prepare a
medicament to treat disease or condition in a mammal in need
thereof, wherein mammal would receive symptomatic relief from the
administration of a therapeutically effective amount of a
crystalline Form I or II. The crystalline Forms I and II may be
administered in combination with other medications for additive or
synergistic therapeutic benefit for a given disease. Diseases
include, but are not limited to, those described below. Medications
include, but are not limited to, drugs which are approved for a
given indication e.g. acetylcholinesterase inhibitors for
Alzheimer's Disease.
[0084] Because Form I is very stable and can be stored for a
considerable length of time prior to its use in the preparation of
a drug product, Form I is useful in the manufacture of drug product
even when the manufacturing process, i.e., the formulation of the
active ingredient, causes some or all of the Form I to convert to
another form.
[0085] The crystalline Forms I and II may be formulated as
solutions or suspensions, in the form of tablets, capsules (each
including timed release and sustained release formulations), pills,
oils, powders, granules, elixirs, tinctures, suspensions, syrups,
emulsions, microemulsions, or with excipients. Likewise, they may
also be administered by any conventional route, for example in
intravenous (both bolus and infusion), intraperitoneal,
intraocularly, subcutaneous, intramuscular form, enterally,
preferably orally (e.g., in the form of tablets or capsules), or in
a nasal, buccal, sub-lingual, transdermal, or a suppository form,
using well known formulations to those of ordinary skill in the
pharmaceutical arts. In addition, the crystalline Forms I and II
can be administered in the form of liposomes or the like.
Disintegrators include, without limitation, delivery systems such
as small unilamellar vesicles, large unilamellar vesicles and
multilamellar vesicles. Liposomes can be formed from a variety of
phospholipids, such as cholesterol, stearylamine or
phosphatidylcholines.
[0086] For oral administration in the form of a tablet or capsule,
the crystalline Forms I and II can be combined with an oral,
non-toxic pharmaceutically acceptable inert carrier such as
ethanol, glycerol, water and the like. Moreover, when desired or
necessary, suitable binders, lubricants, disintegrating agents and
coloring agents can also be incorporated into the mixture. Suitable
binders include starch, gelatin, natural sugars such as glucose or
beta-lactose, corn sweeteners, natural and synthetic gums such as
acacia, tragacanth or sodium alginate, carboxymethylcellulose,
polyethylene glycol, waxes and the like. Suitable lubricants used
in these dosage forms include, for example, sodium oleate, sodium
stearate, magnesium stearate, sodium benzoate, sodium acetate,
sodium chloride and the like. Suitable disintegrating agents are,
for example, starches, carboxymethylstarch sodium, crosscarmellose
sodium and the like. Examples of the suitable coloring agents are
iron sesquioxide, yellow iron sesquioxide, amaranth, erythrosine,
tartrazine, Sunset Yellow FCF and the like.
[0087] The dosage regimen for the crystalline Forms I and II is
selected in accordance with a variety of factors including type,
species, age, weight, sex and medical condition of the patient; the
severity of the condition to be treated; the route of
administration; the renal and hepatic function of the patient. An
ordinarily skilled physician or veterinarian can readily determine
and prescribe the effective amount of the drug required to prevent,
counter or arrest the progress of the condition.
[0088] In one embodiment satisfactory results in animals are
indicated to be obtained at a daily dosage of from about 0.1 to
about 600 mg or from about 0.01 to about 5 mg/kg animal body
weight.
[0089] Injected intravenous, subcutaneous or intramuscular dosages
of the crystalline Forms I and II, when used for the indicated
effects, will range between about 0.001 to 1.0 mg/kg. Furthermore,
the crystalline Forms I and II can be administered in intranasal
form via topical use of suitable intranasal vehicles, or via
transdermal routes, using those forms of transdermal skin patches
well known to those of ordinary skill in that art. To be
administered in the form of a transdermal delivery system, the
dosage administration can be continuous rather than intermittent
throughout the dosage regimen. Transdermal delivery can also be
achieved using approaches known to those skilled in the art.
[0090] Diseases that may be treated using the crystalline Forms I
and II include, but are not limited to: condition cognitive and
attention deficit symptoms of Alzheimer's, neurodegeneration
associated with diseases such as Alzheimer's disease, pre-senile
dementia (mild cognitive impairment), senile dementia,
schizophrenia, psychosis attention deficit disorder, attention
deficit hyperactivity disorder, mood and affective disorders,
amytrophic lateral sclerosis, borderline personality disorder,
traumatic brain injury, behavioral and cognitive problems
associated with brain tumors, AIDS dementia complex, dementia
associated with Down's syndrome, dementia associated with Lewy
Bodies, Huntingdon disease, depression, general anxiety disorder,
age related macular degeneration, Parkinson's disease, tardive
dyskinesia, Pick's disease, post traumatic stress disorder,
dysregulation of food intake including bulimia and anorexia
nervosa, withdrawal symptoms associated with smoking cessation and
dependant drug cessation, Gilles de la Tourette's Syndrome,
glaucoma, neurodegeneration associated with glaucoma or symptoms
associated with pain or is the treatment and/or prophylaxis for the
improvement of perception, concentration, learning and/or
memory.
EXEMPLIFICATION
[0091] The present invention is illustrated by the following
examples, which are not intended to be limiting in any way.
Example 1
Preparation of the crystalline Form I
[0092]
(R)-7-Chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride was synthesized by the procedure described in US
2005-0119325. To prepare Form I, 1.0 Kg of the compound was
dissolved in acetonitrile (5 L) and heated to 72-78.degree. C. Once
at this temperature, water (0.5 L) was added. The mixture was
cooled to 50-60.degree. C., wherein crystals are just visible and
seed with Form I seed crystals. The mixture was held for a minimum
of 2 hours, and then acetonitrile (20 L) was added while
maintaining an internal temperature of 50-60.degree. C. The
material was cooled to 5-10.degree. C. Crystals were isolated by
vacuum filtration and washed with acetonitrile (2 L). The material
was dried at 40.degree. C. in a vacuum oven with humidity control
to provide 0.8 kg of pure Form I.
Example 2
Preparation of the Crystalline Form I
[0093] Acetonitrile (90 mL) and water (10 mL) were mixed at room
temperature. 1.0 ml of this solution was added to 100.7 mg of the
crystalline Form I of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate. This suspension was stirred at
80.degree. C. until solid component was dissolved, then the
temperature was decreased to 40.degree. C. for 80 minutes. During
the cooling, spontaneous crystallization was observed round
52.degree. C. To the suspension, 2.40 ml of acetonitrile was
dropped slowly, and then the temperature was decreased to
10.degree. C. for 60 minutes. The suspension was stirred at same
temperature for 15 hours, and then the solid was filtered and
washed with 0.20 ml of acetonitrile. After vacuum drying, 81.1 mg
of the crystalline Form I was recovered.
Example 3
Preparation of the Crystalline Form II
[0094] Acetonitrile (90 mL) and water (10 mL) were mixed at room
temperature. 1.0 ml of this solution was added to 100.9 mg of the
crystalline Form I of
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate. This suspension was stirred at
80.degree. C. until solid component was dissolved, then the
temperature was decreased to 10.degree. C. for 140 minutes. During
the cooling, spontaneous crystallization was observed round
51.degree. C. The suspension was stirred at same temperature for 15
hours, then the solid was filtered and washed with 0.20 ml of
acetonitrile. After vacuum drying, 48.7 mg of the crystalline Form
II was recovered.
Example 4
Preparation of the Crystalline Form II
[0095]
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
hydrochloride monohydrate (462 g) was triturated in 2308.5 mL
acetonitrile and 230.85 mL of water at ambient temperature for 4.75
hours. The produced was isolated by filtration and dried to afford
314 g of isolated pure Form II.
Example 5
Phase Diagram in Aqueous Acetonitrile
(1) Solubility Measurements of Forms I and II
[0096] Solubility of Forms I and II was measured at various
temperatures between 5.degree. C. and 45.degree. C. in aqueous
acetonitrile in which water concentration was from 0 to 10 v/v %
respectively.
[0097] Solubility was measured according to the following
procedure. Form I or II crystals and an aqueous acetonitrile were
added to a glass vessel. The mixture was stirred with a
Teflon-coated magnetic stirrer bar at a defined temperature
controlled with aluminum block. The liquid phase was sampled
periodically, and the concentration of the compound was measured
with high performance liquid chromatography (HPLC). Solid material
was also collected at the same time to identify the crystal form
using XRPD. In analyzing the time course of the change in
concentration, that plateau zone was identified as an equilibrium
condition, and the mean value of these concentrations was defined
as "solubility" under that condition. Measured solubility is
summarized in Table 1.
TABLE-US-00001 TABLE 1 Results of the solubility measurement
Conditions Water Stable from concentration Temp Solubility
(Estimated from [v/v %] [.degree. C.] Form I Form II Form X
solubility) 0 5 1.0 * ** I 25 1.3 * ** I 2 5 2.4 2.6 ** I 25 4.1
4.7 4.2 I 45 8.7 * 9.1 I 3.5 12.5 5.4 5.7 ** I 37.5 10.0 * 10.3 I 6
5 12.8 11.2 ** II 25 17.1 16.7 ** II 45 27.2 29.6 ** I 8.5 12.5
27.6 25.1 ** II 37.5 44.4 44.4 ** I and II 10 5 * 29.7 ** II 25
47.5 44.6 ** II 45 71.6 74.5 ** I * Could not measure ** Did not
conduct
(2) Solublity Equations were Modeled Using JMP 6 (SAS
Institute)
[0098] With the response surface method, measured solubility values
were applied to equation (1) to obtain solubility models as a
function of temperature and water concentration. W' and T' were
defined as equations (2) and (3) respectively. Here, C*.sub.x, W
and T mean solubility of a certain crystal form, water
concentration in aqueous acetonitrile (v/v %) and temperature
(.degree. C.) respectively. Constant values from a, b, c, d and f
were determined by applying measured solubility values with least
squares fitting method within the range of 2 to 10 v/v % water
concentration and within the range of 5 to 45.degree. C.
Perspective of defects or accuracy, measured solubility values at
2%-45.degree. C. of both forms, 3.5%-37.5.degree. C. of form II and
10%-10.0.degree. C. of form I are excluded to build mathematical
formulas.
C*.sub.x=Ex.sub.p(a+bW'+cT'+dW'T'+eW'.sup.2+fT'.sup.2) (1)
W'=(W-6)/4 (2)
T'=(T-25)/20 (3)
[0099] Fitting results showed that constants were determined
successfully, and these models can describe solubility within the
range with only minor deviation. Obtained solubility equations of
Forms I and II are shown in equation (4) and (5) respectively.
C*.sub.I=Exp(2.8448+1.2517W'+0.4185T'-0.1086W'T'-0.2249W'.sup.2+0.0681T'-
.sup.2) (4)
C*.sub.II=Exp(2.8389+1.1503W'+0.5101T'-0.0638W'T'-0.1888W'.sup.2+0.0488T-
'.sup.2) (5)
(3) Development of Phase Diagram
[0100] Thermodynamic relationship between polymorphic crystal
phases is consistent with solubility. Based on the results of the
solubility measurements, it is apparent that thermodynamic
relationship between forms I and II crystals is enantiotropy.
Boundary of stable crystal form should exist in the range that
solubility measurement was carried out. At boundary condition,
solubility of forms I and II should be same. Hence, boundary
condition can be induced from equation (4) and (5) and simplified
as described in equation (6).
0.0059|0.1014W'-0.0916T'-0.0448W'T'-0.0361W'.sup.2|0.0193T'.sup.2=0
(6)
[0101] By solving boundary equation (6), boundary condition can be
determined. Solved values are shown in Table 2. By plotting the
results, phase diagram was described in FIG. 1. For convenience,
this boundary line which obtained from equation (6) was fitted by
fourth degree equation of water concentration. This approximation
formula and its solved values are shown in equation (7) and Table 2
respectively.
T'=0.0056W.sup.4-0.1305W.sup.3+0.2831W.sup.2+11.3942W-31.3235
(7)
TABLE-US-00002 TABLE 2 Solved values of boundary equations Water
concentration: Temperature [.degree. C.] [% v/v] Equation (6)
Equation (7) 3.0 2.34 2.34 3.5 7.26 7.27 4.0 11.86 11.86 4.5 16.08
16.09 5.0 19.91 19.91 5.5 23.33 23.32 6.0 26.31 26.30 6.5 28.85
28.86 7.0 30.97 30.99 7.5 32.69 32.72 8.0 34.03 34.07 8.5 35.03
35.07 9.0 35.73 35.76 9.5 36.16 36.20 10.0 36.35 36.43
Example 6
Inter-Con Version Tests
[0102] Inter-conversion tests were also carried out in order to
confirm reliability of obtained phase diagram of Example 5 (FIG.
1).
[0103] Solvent was added to a glass vessel and temperature was
controlled with aluminum block. Identical amounts of Forms I and II
crystals were added to the vessel. The solutions were stirred for
13 to 40 hr with Teflon-coated magnetic stirrer bar. Solid
component was sampled and analyzed with XRPD to determine its
crystal form.
[0104] The results were summarized in Table 3. These results were
consistent with phase diagram of Example 5.
TABLE-US-00003 TABLE 3 Experimental Results of Inter-conversion
tests Temperature Water concentration run [.degree. C.] [v/v %]
Results 1 10 3.0 I 2 3.5 I 3 4.0 II 4 4.5 II 5 20 4.0 I 6 4.5 I 7
5.0 I 8 5.5 II 9 6.0 II 10 30 5.5 I 11 6.0 I 12 6.5 I 13 7.0 I 14
7.5 II
Example 7
Crystallization Behavior in Aqueous Acetonitrile
(1) Form X
[0105] Form X was found as another solid form in the solubility
study. A typical XRPD pattern of form X is shown in FIG. 2.
(2) Crystallization Behavior in 98 v/v % Aqueous Acetonitrile
[0106] Form I crystals were added to 98 v/v % aqueous acetonitrile
in a glass vessel. Next, 98 v/v % aqueous acetonitrile was added to
make the mixture 40 v/w times relative to the Form I crystal. The
mixture was stirred with Teflon-coated magnetic stirrer bar and
heated to 80.degree. C. with aluminum block. After the crystals
were dissolved, the mixture was cooled to a determined temperature
at the rate of 30.degree. C. per hour. After a determined holding
time, Form I crystals were added as seed crystals according to
object of an experiment. Precipitates were sampled periodically and
analyzed by XRPD.
[0107] Initial precipitates in 98 v/v % aqueous acetonitrile system
were confirmed as Form X. Spontaneous transformation from Form X to
Form I was not observed within 16 hours. From the results of the
seeded experiments, it was estimated that Form I is more stable
than Form X regardless of temperature. Form X could be recovered in
84.7% yield.
TABLE-US-00004 TABLE 4 Results of crystallization experiments in 98
v/v % aqueous acetonitrile Temperature Holding time Run [.degree.
C.] [hr] Crystalor form 1 60 0 X 40 0 X 10 0 X 15 X Seeding* 2 X 8
X 27 X(I)** 2 60 0 X 40 0 X 16 X Seeding* 2 I + X 8 I 27 I 3 60 0 X
40 0 X 10 0 X 15 X -- X *ca. 4% w/w Form I crystals **Slight amount
of Form I was detected
(3) Transformation Behavior in 98 v/v % Aqueous Acetonitrile
[0108] Form I crystals and 40 v/w times volume of 98 v/v % aqueous
acetonitrile were added to a glass vessel. The mixture was stirred
with Teflon-coated magnetic stirrer bar and heated to 80.degree. C.
with aluminum block. After dissolved, solution was cooled to
5.degree. C. at the rate of 30.degree. C. per hour. To the slurry
of Form X, 10 w/w % of Form I crystals were added as seed crystals
at 5.degree. C., then controlled to a certain temperature. Samples
of solid material were analyzed by XRPD on a periodic basis.
[0109] Transformation from Form X to Form I was observed above
ambient temperature. This tendency to transform was also observed
at 5.degree. C. In 98 v/v % aqueous acetonitrile system, it was
estimated that Form I is more stable than Form X regardless of
temperature though transformation kinetics was extremely slow at a
low temperature.
TABLE-US-00005 TABLE 5 Results of transformation experiments in 98
v/v % aqueous acetonitrile Temperature Time Run [.degree. C.] [hr]
Crystal for 1 5 0* X 16 X 40 X(I)** 2 25 0* X 16 I + X 40 I 3 40 0*
X 16 I 40 I *Right after the seeding at 5.degree. C. **Slight
amount of Form I was detected
(4) Transformation Behavior in 97 v/v % Aqueous Acetonitrile
[0110] Form X crystals and 97 v/v % aqueous acetonitrile were added
to a glass vessel. The mixture was stirred with Teflon-coated
magnetic stirrer bar at the temperature controlled with aluminum
block. Solid component was sampled periodically and analyzed by
XRPD to determine the crystal form.
[0111] Spontaneous transformation from Form X to Form I was
observed in all experiments. It was estimated that Form I is more
stable than Form X regardless of temperature in 97 v/v % aqueous
acetonitrile.
TABLE-US-00006 TABLE 6 Results of transformation experiments in 97
v/v % aqueous acetonitrile Temperature Time Run [.degree. C.] [hr]
Crystal form 1 10 1 X 3 X 21 I 2 20 1 X 3 X 21 I 3 30 1 X 3 I 21 I
4 40 1 X 3 I 21 I 5 50 1 I 3 I 21 I
Example 8
Inter-Conversion Tests in Various Solvents
[0112] A mixture of crystalline Forms I and II (25 mg/25 mg) was
stirred in 0.5 mL of each organic solvent/water shown in Table 7
for 3 days at 5, 25, 40 and 60.degree. C., respectively, and the
precipitates were filtrated, then the crystal forms were confirmed
by XRPD. The results were shown in the Table 7.
TABLE-US-00007 TABLE 7 Results of inter-conversion tests in various
solvents Water Concentration Temperature [.degree. C.] Solvent [v/v
%] 5 25 40 60 2-Propanol 0 I(II) I(II) I(II) I 2-Propanol 2 I(II) I
I X 2-Propanol 5 I I I I 2-Propanol 10 II I I sol 1-Propanol 0 I/X
I/X I/II I/II 1-Propanol 2 I X I sol 1-Propanol 5 I I I(II) sol
1-Propanol 10 II sol sol sol Acetone 0 I I/II I/X -- Acetone 2 I I
I -- Acetone 5 I I I -- Acetone 10 II I I -- 1-Butanol 0 I I I I
1-Butanol 2 I I I I 1-Butanol 5 II I I I 1-Butanol 10 II sol Sol
sol 2-Butanol 0 I I I I 2-Butanol 2 I I I I 2-Butanol 5 II I I I
2-Butanol 10 II II II sol Acetonitrile 0 I/II I I I Acetonitrile 2
I/II I I I Acetonitrile 5 II I I I Acetonitrile 10 II II I/II sol
2-Butanone 0 I I/X I/X I/X 2-Butanone 2 II I I I 2-Butanone 5 II II
II I 2-Butanone 10 II sol sol sol I: form I II: form II I(II):
form-I (small amount of form-II) I/II: form-I/II mixture I/X:
form-I/X mixture Sol: solution
Example 9
Relationship Between Water Concentrations and the Values of Water
Activity at Various Temperatures
[0113] The values of water activity of various water concentrations
(i.e., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 20 v/v %) in various
organic solvents (i.e., 1-propanol, 2-propanol, 1-butanol,
2-butanol, acetone, 2-butanone, and acetonitrile) at various
temperatures (i.e., 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55
and 60.degree. C.), respectively, were calculated using COSMOTHERME
version 2.1 based on Cosmo-RS method.
[0114] The values of water concentrations (v/v %) were calculated
on the boundary line (equation (6)) between Form I and Form II at
various temperatures (i.e., 0, 5, 10, 15, 20, 25, 30, and
35.degree. C.), and converted into the values of water activity
using a regression curve of the cubic equation for plots of the
values of water activity versus water concentrations at various
temperatures (FIG. 3). Table 8 indicates the relationship between
water contents (v/v %) and the values of water activity on the
boundary line of the phase diagram. The values of water activity
and the corresponding temperatures were fitted by equation (7) with
a good correlation (correlation coefficient: 0.997).
T=183X-64.2 (7)
TABLE-US-00008 TABLE 8 Relationship between water concentrations
(v/v %) and the values of water activity at various temperatures
Temperature Water Concentration [.degree. C.] [V/V %] Water
activity 0 2.77 0.349 5 3.27 0.382 10 3.79 0.411 15 4.37 0.437 20
5.01 0.460 25 5.77 0.483 30 6.76 0.509 35 8.48 0.551
[0115] The results of the inter-conversion tests were plotted and
the boundary line by equation (7) was drawn on the phase diagram of
Form I and Form II as shown in FIG. 4. The boundary line
approximately separated the Form I and Form II in all experimented
solvent systems.
Example 10
Crystallization of Crystalline Form I
(1) 1-Propanol
[0116] Crystalline Form I (100.1 mg) was dissolved in 1 mL of
1-propanol/water (9:1(v/v)) at 70.degree. C. The mixture was
gradually cooled to 60.degree. C. during 20 minutes, and 1 mL of
1-propanol was added thereto. The mixture was again gradually
cooled to 5.degree. C. during 110 minutes with stirring. Then 3 mL
of 1-propanol was added thereto, and the mixture was stirred at
5.degree. C. overnight. The crystals were isolated by filtration in
vacuo and dried under air at room temperature to give crystalline
Form I (11.1 mg).
(2) 2-Propanol
[0117] Crystalline Form I (100.1 mg) was dissolved in 1 mL of
2-propanol/water (9:1(v/v)) at 90.degree. C. The mixture was
gradually cooled to 25.degree. C. during 130 minutes, and 1 mL of
2-propanol was added thereto. The mixture was again gradually
cooled to 5.degree. C., and 3 mL of 2-propanol was added. The
mixture was stirred at 5.degree. C. for 4 days. The crystals were
isolated by filtration in vacuo and dried under air at room
temperature to give crystalline Form I (48.9 mg).
(3) 1-Butanol
[0118] Crystalline Form I (100.0 mg) was dissolved in 1 mL of
1-butanol/water (9:1(v/v)) at 60.degree. C., and 1 mL of 1-butanol
was added thereto. The mixture was gradually cooled to 25.degree.
C. during 70 minutes, and 3 mL of 1-butanol was added thereto. The
mixture was again gradually cooled to 5.degree. C., and stirred at
5.degree. C. overnight. The crystals were isolated by filtration in
vacuo and dried under air at room temperature to give crystalline
Form I (29.0 mg).
(4) 2-Butanol
[0119] Crystalline Form I (100.0 mg) was dissolved in 1 mL of
2-butanol/water (9:1(v/v)) at 90.degree. C. The mixture was
gradually cooled to 60.degree. C. during 60 minutes, and 1 mL of
2-butanol was added thereto. The mixture was gradually cooled to
25.degree. C. during 70 minutes, and 3 mL of 2-butanol was added
thereto. The mixture was again gradually cooled to 5.degree. C.,
and stirred at 5.degree. C. overnight. The crystals were isolated
by filtration in vacuo and dried under air at room temperature to
give crystalline Form I (52.1 mg).
(5) Acetone
[0120] Crystalline Form I (100.2 mg) was dissolved in 1.3 mL of
acetone/water (9:1(v/v)) under reflux. The mixture was gradually
cooled to 25.degree. C. during 70 minutes, and 1.3 mL of acetone
was added thereto. The mixture was gradually cooled to 5.degree.
C., and 3.9 mL of acetone was added thereto. The mixture was
stirred for 4 days at 5.degree. C. The crystals were isolated by
filtration in vacuo and dried under air at room temperature, to
give crystalline Form I (74.5 mg).
(6) 2-Butanone
[0121] Crystalline Form I (100.3 mg) was dissolved in 1 ml of
2-butanone/water (9:1(v/v)) at 60.degree. C. 4 mL of 2-butanone was
added thereto. The mixture was gradually cooled to 25.degree. C.
during 70 minutes, and the mixture was stirred at room temperature
for 4 days. The crystals were isolated by filtration in vacuo and
dried under air at room temperature to give crystalline Form I
(70.0 mg).
Example 11
Crystallization of Crystalline Form II
(1) 1-Propanol
[0122] Crystalline Form I (100.0 mg) was dissolved in 1 mL of
1-propanol/water (9:1(v/v)) at 60.degree. C. The mixture was
gradually cooled to 5.degree. C. during 110 minutes, and was
stirred for 4 days at 5.degree. C. The crystals were isolated by
filtration in vacuo and dried under air at room temperature to give
crystalline Form II (11.0 mg).
(2) 2-Propanol
[0123] Crystalline Form I (100.3 mg) was dissolved in 1 mL of
2-propanol/water (9:1(v/v)) at 90.degree. C. The mixture was
gradually cooled to 5.degree. C. during 170 minutes, and was
stirred for 5 days at 5.degree. C. The crystals were isolated by
filtration in vacuo and dried under air at room temperature to give
crystalline Form II (40.2 mg).
(3) 1-Butanol
[0124] Crystalline Form I (100.1 mg) was dissolved in 1 mL of
1-butanol/water (9:1(v/v)) at 70.degree. C. The mixture was
gradually cooled to 5.degree. C. during 130 minutes, and 1 mL of
1-butanol was added thereto. The mixture was stirred for 4 days at
5.degree. C. The crystals were isolated by filtration in vacuo and
dried under air at room temperature to give crystalline Form II
(31.6 mg).
(4) 2-Butanol
[0125] Crystalline Form I (100.2 mg) was dissolved in 1 mL of
2-butanol/water (9:1(v/v)) at 90.degree. C. The mixture was
gradually cooled to 5.degree. C. during 170 minutes, and 1 mL of
2-butanol was added thereto. The mixture was stirred for 4 days at
5.degree. C. The crystals were isolated by filtration in vacuo and
dried under air at room temperature to give crystalline Form II
(54.7 mg).
(5) Acetone
[0126] Crystalline Form I (100.3 mg) was dissolved in 1.2 mL of
acetone/water (9:1(v/v)) under reflux. The mixture was gradually
cooled to 5.degree. C. 110 minutes, and 1 mL of acetone was added
thereto. The mixture was stirred for 4 days at 5.degree. C. The
crystals were isolated by filtration in vacuo and dried under air
at room temperature to give crystalline Form II (36.4 mg).
(6) 2-Butanone
[0127] Crystalline Form I (100.2 mg) was dissolved in 1 mL of
2-butanone/water (9:1(v/v)) at 60.degree. C. The mixture was cooled
to 5.degree. C. during 110 minutes. Next, 4 mL of 2-butanone was
added thereto. The mixture was stirred for 4 days at 5.degree. C.
The crystals were isolated by filtration in vacuo and dried under
air at room temperature to give crystalline Form II (76.7 mg).
Example 12
Physical Data of Forms I and II
(1) Powder X-Ray Diffraction (XRD)
[0128] Diffraction patterns were taken at room temperature and
humidity using a Rigaku RINT-TTRIII diffractometer with Cu K.alpha.
radiation. The diffraction angle, 20, was scanned from 3 to 40 at
rate of 2.degree./minute at a step size of 0.02.degree.. The
results of this analysis are shown in FIGS. 5 and 6, which are the
same as those measured against an internal silicon standard.
(2) Solubility
[0129] Excess amount of the samples, Forms I and II, were suspended
in water, and were equilibrated by shaking for 20 minutes at
25.degree. C. or 37.degree. C., respectively. The amounts of
dissolved the compound were determined using a Waters alliance HPLC
system 2695, detected by UV 210 nm. The results of this analysis
are shown in Table 9.
TABLE-US-00009 TABLE 9 Solubility in water of the crystalline Forms
I and II Temperature Form I Form II 25.degree. C. 39 mg/mL 30 mg/mL
37.degree. C. 90 mg/mL 54 mg/mL
(3) Hygroscopicity
[0130] The hygroscopicity of Forms I and II were investigated using
a Surface measurement systems, DVS-1, between 10% RH and 90% RH at
25.degree. C. There was no hygroscopicity in Form I. On the other
hand, there was a hygroscopicity in Form II, and the water value of
approximately 4% was increased and decreased between 10% RH and 90%
RH by absorption and desorption of ca. 1 mol of channel water.
INCORPORATION BY REFERENCE
[0131] The entire contents of all patents, published patent
applications and other references cited herein are hereby expressly
incorporated herein in their entireties by reference.
EQUIVALENTS
[0132] Those skilled in the art will recognize, or be able to
ascertain using no more than routine experimentation, numerous
equivalents to the specific procedures described herein. Such
equivalents were considered to be within the scope of this
invention and are covered by the following claims. Moreover, any
numerical or alphabetical ranges provided herein are intended to
include both the upper and lower value of those ranges. In
addition, any listing or grouping is intended, at least in one
embodiment, to represent a shorthand or convenient manner of
listing independent embodiments; as such, each member of the list
should be considered a separate embodiment.
* * * * *